Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Phase 3

Not yet recruiting

• Conditions: Breast Neoplasms; Locally Advanced or Metastatic Breast Cancer
• Interventions: Drug: Utidelone plus Intermittent Capecitabine; Drug: Utidelone plus Metronomic Capecitabine; Drug: Taxane plus Metronomic Capecitabine; Drug: Taxane plus Intermittent Capecitabine

• Registration Number: NCT05172518
• Lead Sponsor: Sun Yat-sen University

Brief Summary

It is a phase III trial to explore the efficacy and safety of utidelone plus capecitabine versus taxane plus capecitabine in HER2-negative locally advanced or metastatic breast cancer and the differences of metronomic capecitabine and intermittent capecitabine in combination chemotherapy.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-12
• Study First Submitted: 2021-12-27
• Study First Submitted QC: 2021-12-27
• Last Update Submitted: 2021-12-27
• Study First Posted: 2021-12-29
• Last Update Posted: 2021-12-29
• Study Start: 2022-03-01
• Primary Completion: 2027-03-01
• Study Completion: 2030-03-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 512

Inclusion Criteria

• Signed Informed Consent Form;

• Women aged ≥ 18 years;

• Patients with locally advanced or metastatic, histologically or cytologically documented breast cancer;

• The primary tumor and metastases (if aspirated) are both HER2-negative;

• Eastern Cooperative Oncology Group (ECOG) score [0-2] points;

• Measurable disease according to RECIST version 1.1;

• Previous chemotherapy with taxane for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed ≥12 months before randomisation;

• No more than one prior chemotherapy regimen for inoperable locally advanced or metastatic HER2-negative breast cancer;

• Hormone receptor positive patients are allowed no more than two lines of prior endocrine therapy for metastatic disease (including CDK4/6 inhibitors, chidamide and PI3K inhibitors, etc.);

• Patients must have recovered to ≤ Grade 1 (CTCAE v5.0) from all toxicities related to prior antineoplastic therapy. However, patients with any grade of alopecia are allowed ;

• Patients with asymptomatic CNS metastases may be enrolled, if:

  1. Intracranial lesions are evaluable and eligible for systemic therapy only in the absence of extracranial evaluable lesions, or
  2. Patients with stable intracranial lesions after local treatment while there are extracranial evaluable lesions ;

• Adequate hematological, hepatic and renal function;

• Women of child bearing potential must agree to use a contraceptive method during the treatment period and for at least 90 days after the last dose of experiment treatment;

• Life expectancy of at least 12 weeks;

• Patients must be able to participate and comply with treatment and follow-up.

Exclusion Criteria

• HER-2 positive (IHC + + +, or FISH positive);
• Other malignancies (including primary brain or leptomeninges-related tumors) within the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ;
• Patients who have received anti-tumor therapy within 4 weeks prior to the start of study treatment, including chemotherapy, radical radiotherapy, hormone therapy, biological therapy, immunotherapy or anti-tumor Chinese medicine therapy;
• Patients who have undergone major organ surgery (excluding needle biopsy) or have significant trauma within 4 weeks before the first dose of treatment, or anticipating for a major surgical procedure during the study;
• Symptomatic peripheral neuropathy or CTCAE 5.0 grade ≥ 2;
• Experienced grade 3 or above nervous system-related adverse events after treatment with anti-microtubule drugs;
• Received taxane and/or capecitabine-containing adjuvant/neoadjuvant chemotherapy within 1 year prior to the first study treatment;
• Received prior first-line chemotherapy containing a taxane or capecitabine;
• Symptomatic central nervous system metastases;
• Inability to take or absorb oral medications;
• Pregnant or lactating women;
• Known or suspected hypersensitivity to any of the study drugs or excipients;
• Any other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that precludes study treatment implementation or follow-up ；
• Any other condition that the investigator considers inappropriate to participate in this trial .
• Use of corticosteroids is prohibited.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
Arm B	Utidelone plus Intermittent Capecitabine	Utidelone plus Intermittent Capecitabine
Arm D	Utidelone plus Metronomic Capecitabine	Utidelone plus Metronomic Capecitabine
Arm C	Taxane plus Metronomic Capecitabine	Taxane plus Metronomic Capecitabine
Arm A	Taxane plus Intermittent Capecitabine	Taxane plus Intermittent Capecitabine

Primary Outcome Measures

Name	Time	Method
Progression Free Survival (PFS)	up to 60 months	Time from randomization to progression or death (whichever occurred first).

Secondary Outcome Measures

Name	Time	Method
Objective response rate (ORR)	up to 60 months	The proportion of patients with a best response of CR or PR, according to RECIST 1.1 criteria.
Overall survival (OS)	up to 60 months	Time from randomization to death Time from randomization to death Time from randomization to death Time from randomization to death.
Time to response (TTR)	up to 60 months	the time from randomization to the first documentation of disease response (CR or PR).
Duration of response (DOR)	up to 60 months	the time from the first evaluation that criteria for CR or PR are met until PD or death is observed, whichever occurs first, calculated only for patients whose best response is evaluated as CR or PR.

Trial Locations

Locations (1)

Shusen Wang; 🇨🇳 Guangzhou, Guangdong, China